argenx SE
XBRU:ARGX
argenx SE
XBRU:ARGX
Price:
367.6 EUR
0.27%
Market Closed
Updated:
May 8, 2024
argenx SE
Operating Income
|
argenx SE
Operating Income Peer Comparison
Comparables:
PHARM
PRQR
QURE
MRUS
N
NAMS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
argenx SE
XBRU:ARGX
|
Operating Income
-$420.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Income
-$21.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Income
-€31.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Income
-$282.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-24%
|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Income
-$156.5m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Operating Income
-€3.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is argenx SE's Operating Income?
Operating Income
-420.6m
USD
-420.6m
USD
Based on the financial report for Dec 31, 2023, argenx SE's Operating Income amounts to -420.6m USD.
What is argenx SE's Operating Income growth rate?
Operating Income CAGR 5Y
-36%
-36%
Over the last year, the Operating Income growth was 41%. The average annual Operating Income growth rates for argenx SE have been 4% over the past three years , -36% over the past five years .
You don't have any saved screeners yet
